Enrichment Materials

Deep-dive resources for researchers, advanced learners, and clinical scholars. Includes extended literature review, additional case studies, interactive clinical tools, and comprehensive protocol references.

Extended Literature Review

Low-Dose Buprenorphine Induction

Hammig et al., J Addict Med. 2016;10(4):264-269

Pioneering study establishing the feasibility of low-dose buprenorphine initiation without requiring patients to enter withdrawal first. Demonstrated successful transitions in patients maintained on full agonist opioids.

Key Findings

  • Successful induction in 85% of patients using microdosing approach
  • No cases of precipitated withdrawal in low-dose group
  • Patient satisfaction scores higher with gradual transition

Critical Appraisal

PubMed PDF

Micro-Induction of Buprenorphine/Naloxone: A Review

Ahmed et al., Can J Addict. 2021;12(1):13-22

Comprehensive review of microdosing protocols, including various dosing schedules and patient populations. Synthesizes evidence from multiple small studies and case series.

Key Findings

  • Multiple successful microdosing protocols exist (Bernese method, etc.)
  • Particularly effective for patients on long-acting opioids
  • Reduces dropout during induction phase

Critical Appraisal

PubMed PDF

Buprenorphine Micro-Dosing in the Era of Fentanyl

De Aquino et al., Drug Alcohol Depend. 2023;243:109725

Contemporary analysis of microdosing protocols specifically adapted for fentanyl-exposed patients. Addresses tissue depot effects and unpredictable withdrawal timing with fentanyl analogues.

Key Findings

  • Fentanyl lipophilicity creates prolonged elimination
  • COWS unreliable predictor for fentanyl patients
  • Microdosing eliminates withdrawal window uncertainty
  • Retention rates improved vs standard induction in fentanyl cohort

Critical Appraisal

PubMed PDF

MOTHER Study: Buprenorphine vs Methadone in Pregnancy

Jones et al., N Engl J Med. 2010;363(24):2320-2331

Landmark randomized controlled trial comparing buprenorphine and methadone in pregnant women with opioid use disorder. Primary outcome was neonatal abstinence syndrome (NAS) severity and treatment requirements.

Key Findings

  • Buprenorphine associated with shorter NAS duration (4.1 vs 5.5 days)
  • Less morphine needed for NAS treatment with buprenorphine
  • No significant difference in maternal outcomes
  • Both medications considered safe and effective in pregnancy

Critical Appraisal

PubMed PDF

Additional Case Studies

Case 3: Polysubstance Use with Benzodiazepine Dependence

Patient: 42M Complexity: High Method: Low-dose

Background

  • 10-year history of opioid use disorder (heroin, now fentanyl)
  • Concurrent alprazolam 2mg TID prescribed for anxiety
  • Previous failed induction due to oversedation concerns
  • Multiple ED visits for overdose (opioid + benzo combination)

Clinical Decision-Making

  • Recognized that abrupt benzo discontinuation is dangerous
  • Coordinated with prescribing provider for gradual taper
  • Selected low-dose buprenorphine induction to minimize additional sedation risk
  • Prescribed naloxone to patient and household members

Outcome

  • Successful transition over 10 days (slower than standard protocol)
  • Alprazolam tapered from 6mg/day to 2mg/day over 8 weeks
  • Stabilized on buprenorphine 16mg/day + clonidine PRN
  • No overdose events in 6-month follow-up

Teaching Points

  • Concurrent benzodiazepine use is NOT an absolute contraindication
  • Slower induction and closer monitoring required
  • Harm reduction approach: prioritize OUD treatment while managing benzo risk
  • Coordination with other prescribers is essential

Case 4: High-Dose Methadone Transition

Patient: 35F Complexity: High Method: Modified standard

Background

  • Stable on methadone 80mg/day for 3 years at OTP
  • Wishes to transition to office-based buprenorphine for convenience
  • Lives 90 minutes from nearest OTP

Challenge

High-dose methadone has extremely long half-life. Standard guidelines suggest 36-72 hours, but tissue accumulation from chronic dosing may require longer.

Approach

  • Taper methadone to 30mg/day over 4 weeks (coordinated with OTP)
  • Wait 72 hours after last methadone dose
  • COWS score 14 at assessment
  • Start buprenorphine 2mg, reassess at 2 hours
  • Some precipitated withdrawal noted (patient described as "different from normal withdrawal")
  • Supported with clonidine and NSAIDs, continued induction

Outcome

  • Day 2: 8mg, Day 3: 16mg — stabilized at 20mg/day
  • Minor precipitated withdrawal resolved within 6 hours
  • Patient reports higher satisfaction with flexibility of office-based care

Case 5: Adolescent OUD with Family Conflict

Patient: 17M Complexity: Moderate Method: Standard

Background

  • Started with prescription oxycodone after wisdom teeth removal
  • Transitioned to illicit pills (fentanyl-adulterated)
  • Parents initially opposed "replacement therapy"
  • COWS 12 at initial visit (18 hours since last use)

Approach

  • Family meeting to discuss neuroscience of addiction and buprenorphine mechanism
  • Emphasized that OUD is medical condition, not moral failing
  • Shared data on relapse rates with vs without MOUD
  • Used low-dose induction given fentanyl exposure

Outcome

  • Parents agreed to 90-day trial
  • Successful transition to buprenorphine 16mg/day
  • Family therapy initiated to address communication patterns
  • Remain abstinent from other substances at 4-month follow-up

Clinical Tools

Buprenorphine Dosing Calculator

Recommended Dose

Select parameters above
Based on SAMHSA TIP 63 guidance

COWS Score Calculator

Total COWS Score

Enter scores above
8-12 = Safe to induce (standard method)

Microdose Schedule Generator

Generated Schedule

Select parameters above

Protocol Reference

Standard Induction Protocol (Quick Reference)

Day Dose Requirements Notes
Day 1 2-4 mg SL COWS ≥8-12; ≥12h since short-acting opioid Reassess at 1-2h; may add 2-4 mg (max 8 mg)
Day 2 8-16 mg SL Symptom control Single dose or BID
Day 3-7 Titrate to 16-24 mg Based on cravings/withdrawal Most stabilize at 16 mg; many need 24 mg

Low-Dose Microdosing Protocol (Quick Reference)

Day Buprenorphine Dose Other Opioid Use Notes
10.5 mg SLContinueStart building receptor occupancy
20.5 mg BID (1 mg total)ContinueGradual increase
31 mg BID (2 mg total)Begin reducingStart transition
42 mg BID (4 mg total)Reduce furtherContinue transition
54 mg BID (8 mg total)DiscontinueFull transition
68 mg BID (16 mg total)NoneMaintenance level
7+Titrate to 16-24 mgNoneStabilization

COWS Scoring Reference

Sign/Symptom Scale Points
Resting Pulse >80 BPM / >100 BPM 1 / 2
Sweating None to Sweat streaming off face 0-4
Restlessness Able to sit still to Unable to sit still 0-4
Pupil Size Pinned to Dilated 0-5
Bone/Joint Aches None to Severe 0-4
GI Upset None to Multiple episodes 0-3
Tremor None to Gross tremor 0-4
Yawning None to >16 times 0-3
Anxiety/Irritability None to Severe 0-4
Gooseflesh Skin None to Severe 0-3

Interpretation: 0-4 = No withdrawal; 5-7 = Mild; 8-12 = Moderate (safe to induce); 13-24 = Moderate-Severe; 25+ = Severe

Teaching Resources

📋 SAMHSA TIP 63

The definitive clinical guidance document. 2024 update includes microdosing protocols.

Access Resource →

🎓 PCSS Training Modules

Free CME-certified training on buprenorphine prescribing with mentorship pairing available.

Access Resource →

📊 COWS Assessment Tool

Printable COWS scale for clinical use and patient self-assessment.

Download PDF →

📱 Telehealth Guidelines

SAMHSA guidance for remote OUD treatment and buprenorphine prescribing.

Access Resource →

👶 Perinatal OUD Toolkit

ACOG/ASAM collaborative guidance for pregnancy and postpartum OUD care.

Access Resource →

⚖️ Legal/Regulatory FAQs

X-waiver elimination guidance, DEA requirements, and state-specific regulations.

Access Resource →